(Sharecast News) - Faron Pharmaceuticals said on Monday that updated results from its phase one and two 'BEXMAB' study showed further improvement in the clinical performance of bexmarilimab, strengthening the drug's profile as a treatment for newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).
The AIM-traded firm said the data, presented at the European Society for Medical Oncology (ESMO) Congress 2025 by Dr Mika Kontro of Helsinki University Hospital, confirmed an 85% objective response rate and a 45% complete remission rate among 20 evaluable treatment-naïve patients treated with bexmarilimab in combination with azacitidine.

It said 55% of those patients showed full clearance of bone marrow blasts, while those with lower baseline blast counts (

• News Channel